Investor relations | LSE: SVNS

Investors

Announcements, reports, presentations and shareholder information for Solvonis Therapeutics plc, a clinical-stage psychedelics company developing therapeutics for addiction, PTSD and depression.

Share price information Corporate presentation

Share price

Investor resourcesPresentations, annual reports, meeting documents, scientific publications and a glossary.View resources RNS announcementsThe latest regulatory news, as released through a Regulatory Information Service.Read announcements Financial reportsAnnual and half-year reports.View reports Share price and capitalShare price and trading information for LSE: SVNS, and issued share capital.View share information Corporate governanceBoard, committees, policies and governance statements.View governance Advisors and analyst coverageThe Company’s advisers and research coverage of Solvonis.View coverage

Latest announcements

All RNS announcements

13 Oct 2026Solvonis and Portugal’s National Addiction Institute sign an MoU to advance planned European expansion of SVN-001 Phase 3 trial 29 Sep 2026SVN-001 Ahead of Established and Emerging AUD Treatments 3 Sep 2026Vital Patent milestone achieved – SVN 114 25 Aug 2026Solvonis Raises £1.3 Million

Annual report and accounts

Read the latest Solvonis annual report and accounts.

Download (PDF)

The Solvonis story in one document

Why now, the strategy, the pipeline, the AUD franchise, the de novo engine, a summary, the catalyst roadmap and the team, with supporting data and references in the appendix.

Information is given as at 16 October 2026 unless stated otherwise. Announcements made through a Regulatory Information Service (RNS) prevail over the presentation.

Download the presentation (PDF) Presentations and webinars

Key characteristics

Late-stage clinical assets, scientifically de-risked, with near-term milestones

Late-stage clinical assets

SVN-001 is in Phase 3 in severe alcohol use disorder (AUD), recruiting in the UK, with Portuguese sites being assessed. SVN-002, an esketamine oral thin film (OTF), has an FDA-agreed 505(b)(2) route to a U.S. Phase 2b.

Scientifically de-risked

Built on ketamine and esketamine, with established pharmacology and an approved precedent in SPRAVATO®. The published SVN-001 Phase 2a/b met one of its two co-primary endpoints. The FDA confirmed that no additional clinical data are needed before the SVN-002 Phase 2b.

Near-term milestones

SVN-015: further studies funded and conducted by the U.S. National Institute on Drug Abuse (NIDA). SVN-002: Investigational New Drug (IND) submission for the U.S. Phase 2b, planned for 2027.

Phase 3

SVN-001 in severe AUD in the UK; 280 planned participants; MoU signed to assess Portuguese sites

505(b)(2)

SVN-002 (esketamine oral thin film, OTF): route agreed with FDA; Phase 2b planning in the U.S.

de novo programmes with composition-of-matter filings: SVN-015 (StUD), SVN-114 (PTSD) and SVN-015 (MDD)

12.5m

people aged 15+ with severe AUD in the UK and EU4 (Company estimate)

11.3m

people aged 12+ with past-year moderate-to-severe AUD in the U.S. (2024)

SVN-001, SVN-002, SVN-015 and SVN-114 are investigational; their safety and efficacy have not been established. FDA feedback is not an approval or a guarantee of any outcome. Timings are indicative and subject to the availability of capital, regulatory feedback and trial progress. Sources: Grabski et al., Am J Psychiatry 2022;179(2):152–162; Solvonis RNS, 21 January 2025 and 13 October 2026; Company information. Epidemiological estimates, not treated or addressable patients; thresholds differ by region, so the two figures are not additive. Sources: Company estimates (July 2026); SAMHSA, 2024 NSDUH.

Investor enquiries and updates

Email info@solvonis.com, or join the mailing list for pipeline updates and events.

Mailing list signup